BASEL, Switzerland,
March 21, 2017 /PRNewswire/ --
Axovant Sciences (NYSE: AXON), a leading clinical-stage
biopharmaceutical company focused on the treatment of dementia,
today announced upcoming presentations at the American Association
for Geriatric Psychiatry (AAGP) Annual Meeting being held in Dallas
March 24-27 and at the American
Academy of Neurology (AAN) Annual Meeting being held in
Boston April 22-28.
AAGP Annual Meeting
The company will present the following:
Intepirdine (RVT-101), a 5-HT6 Receptor Antagonist, as an
Adjunct to Donepezil in Mild-to-Moderate Alzheimer's Disease:
Evaluation of Activities of Daily Living Domains
Date: March 26, 2017
11:30 A.M. – 6:45 P.M. ET
Location: Hilton Anatole Hotel Grand Ballroom
Abstract Number: NR 5
Examining the Clinical Profile of Nelotanserin, a Novel Agent
in Development for Lewy Body Dementia
Date: March 26, 2017
11:30 A.M. – 6:45 P.M. ET
Location: Hilton Anatole Hotel Grand Ballroom
Abstract Number: NR 15
AAN Annual Meeting
The company will present the following:
An Assessment of Dependence in Dementia Using A Conversion
Algorithm of ADCS-ADL to Dependence Scale From a Double Blind
Placebo Controlled Trial of Intepirdine (RVT-101)
Date:
April 25, 2017 8:30 A.M. – 7:00 P.M.
ET
Location: Boston Convention and Exhibition Center
Abstract Number: P3-088
A Phase 2 Study of Nelotanserin, a Novel 5HT2A Receptor
Inverse Agonist, in Dementia with Lewy Bodies and Parkinson's
Disease Dementia Subjects Experiencing Visual
Hallucinations
Date: April 28,
2017 8:30 A.M. –
5:30 P.M. ET
Location: Boston Convention and Exhibition Center
Abstract Number: P6-088
Axovant expects to present detailed results from both Phase 2
studies of nelotanserin in Lewy body dementia patients in the
second half of 2017 following the completion of both studies.
Forward Looking Statement
This press release contains
forward-looking statements, including statements regarding
Axovant's clinical development and regulatory strategy for
intepirdine and nelotanserin. Forward-looking statements can be
identified by the words "believe," "anticipate," "continue,"
"estimate," "project," "expect," "plan," "potential," "intend,"
"will," "would," "could," "should" or the negative or plural of
these words or other similar expressions that are predictions or
indicate future events, trends or prospects.
Forward-looking statements are subject to risks and
uncertainties that could cause actual results to differ materially
and reported results should not be considered as an indication of
future performance. These risks and uncertainties include, but are
not limited to: risks associated with the success, cost and timing
of our product development activities and clinical trials; the
approval and commercialization of intepirdine and nelotanserin; and
increased regulatory requirements. These statements are subject to
the risk that clinical trial data are subject to differing
interpretations, and regulatory agencies, medical and scientific
experts and others may not share Axovant's views of the clinical
study data. In addition, promising interim results or other
preliminary analyses do not in any way ensure that later or final
results in a clinical trial or in related or similar clinical
trials will replicate those interim results. The product discussed
is investigational and not approved and there can be no assurance
that the clinical program for intepirdine or nelotanserin will be
successful in demonstrating safety and/or efficacy, that we will
not encounter problems or delays in clinical development, or that
any of our product candidates will ever receive regulatory approval
or be successfully commercialized.
For a further description of the risks and uncertainties that
could cause actual results to differ from those expressed in these
forward-looking statements, as well as risks relating to Axovant's
business in general, see the "Risk Factors" section of our
quarterly report on Form 10-Q filed with the Securities and
Exchange Commission on February 14,
2017, and other filings that Axovant makes with the SEC from
time to time. These forward-looking statements are based on
information available to Axovant as of the date of this press
release and speak only as of the date of this release. Axovant
disclaims any obligation to update these forward-looking
statements, except as may be required by law.
About Axovant Sciences
Axovant Sciences is a leading
clinical-stage biopharmaceutical company focused on acquiring,
developing and commercializing novel therapeutics for the treatment
of dementia. Axovant intends to develop a pipeline of product
candidates to comprehensively address the cognitive, functional and
behavioral aspects of dementia and related neurological disorders.
Our vision is to become the leading company focused on the
treatment of dementia by addressing all forms and aspects of this
condition.
To view the original version on PR Newswire,
visit:http://www.prnewswire.com/news-releases/axovant-sciences-to-present-at-upcoming-scientific-meetings-300427288.html
SOURCE Axovant Sciences Ltd.